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S U M M A R Y
Despite the high coverage of directly observed treatment (DOTS), tuberculosis (TB) continues to affect
10.4 million people each year, and kills 1.8 million. High TB mortality, the large number of missing TB
cases, the emergence of severe forms of drug resistance, and the slow decline in TB incidence indicate
that merely expanding the coverage of TB services is insufﬁcient to end the epidemic. In the era of the
End TB Strategy, we need to think beyond coverage and start focusing on the quality of the TB care that is
routinely offered to patients in high burden countries, in both public and private sectors. In this review,
current evidence on the quality of TB care in high burden countries, major gaps in the quality of care, and
some novel efforts to measure and improve the quality of care are described. Based on systematic
reviews on the quality of TB care or surrogates of quality (e.g., TB diagnostic delays), analyses of TB care
cascades, and newer studies that directly measure quality of care, it is shown that the quality of care in
both the public and private sector falls short of international standards and urgently needs
improvement. National TB programs will therefore need to systematically measure and improve
quality of TB care and invest in quality improvement programs.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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411. Introduction
 In May 2014, the World Health Assembly approved the End TB
Strategy, which proposes the ambitious target of ending the global
tuberculosis (TB) epidemic by 2035.1 The goal will be met when
TB-related deaths and active TB incidence are reduced by 95% and
90%, respectively, compared with the 2015 values. Are we on track
to reach these goals?
During the directly observed treatment short course (DOTS) era
in the 1990s and early 2000s, high burden countries (HBCs)
focused on achieving ‘coverage’, deﬁned as the availability of free
TB diagnostic and treatment services in all regions or districts of a
country. While nearly all countries have managed to substantially
improve geographic coverage, the ‘quality’ of services has received
little attention. As a result, TB continues to be a major infectious42
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worldwide, with 10.4 million new TB cases and 1.4 million TB
deaths estimated in 2015.2 The World Health Organization (WHO)
estimates the global burden of multidrug-resistant TB and
rifampicin-resistant TB (MDR/RR-TB) to be 3.9% of new cases of
active TB disease and 21% of previously treated cases. Of the
10.4 million TB cases, 4.3 million patients are either not diagnosed
or not notiﬁed to national TB programs. Further, TB incidence is
declining at a very low rate of 1.5% per year.2
These data suggest that the current approach to global TB
control, in which the onus has been on expanding coverage of TB
services, needs to be reconsidered. In the era of the End TB Strategy,
we need to think beyond coverage and start focusing on the quality
of care that is routinely provided to patients in HBCs, in both public
and private sectors.3,4 Quality TB care is patient-centric care that is
consistent with international standards and delivered in an
accessible, timely, safe, effective, efﬁcient, and equitable manner.
In this narrative review, current evidence on quality of TB care in
HBCs, major gaps in quality of care, and some novel efforts atsis care in high burden countries: the urgent need to address gaps
/j.ijid.2016.10.016
ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
46 m
47 ex
48 th
49 su
50 ca
51 us
52 2.
53 
54 po
55 di
56 co
57 co
58 fe
59 liv
60 ha
61 m
62 m
63 
64 di
65 LT
66 Al
67 ca
68 to
69 id
70 (p
71 fu
72 re
73 ne
74 sc
75 re
76 ev
77 
78 po
79 ve
80 Tr
81 in
82 52
83 hi
84 am
85 hi
86 di
87 co
88 pe
89 pr
90 
91 fo
92 tio
93 in
94 th
95 lo
96 pa
97 in
98 ca
99 3.
100 
101 qu
102 In
103 re
104 an
105 tio
106 Of
107 an
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
Figure 1. Losses and drop-outs at each stage of the cascade of care in latent
tuberculosis infection (LTBI). Numbers in parentheses are 95% conﬁdence intervals.
The value for each level is calculated as the product of the value from the
preceding step, multiplied by the pooled estimate for that step (from ﬁxed-effects
analysis).
Source: Alsdurf H et al. Lancet Infect Dis 20167 (reproduced with permission).
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IJID 2747 1–6easuring quality of care are described, primarily through
amples of recent work conducted in India. Where available,
e ﬁndings of systematic reviews on quality of TB care or
rrogates of quality (e.g., TB diagnostic delays), analyses of TB care
scades, and newer studies that directly measure quality of care
ing simulated patients are appraised.
 Quality of care for latent TB infection
The WHO recommends treating latent TB infection (LTBI) in
pulations at high risk of progressing from LTBI to active TB
sease.5 These include patients with speciﬁc immunosuppressive
nditions, notably HIV, and adults and children who have had
ntact with patients with active pulmonary TB (PTB). However,
w HBCs implement these recommendations, even among people
ing with HIV, where the need is most urgent.2 Some TB experts
ve recently argued for expanded and more aggressive imple-
entation of LTBI screening and treatment programs in HBCs to
itigate the incidence of active TB disease.6
There have been several reviews conducted on LTBI screening,
agnosis, and treatment, but few have appraised the quality of
BI care. In the most recent systematic review of 58 studies,
sdurf and colleagues examined patient losses from the cascade of
re for LTBI from the identiﬁcation of those intended for screening
 those who completed treatment (Figure 1).7 The authors
entiﬁed areas where LTBI care has been successfully delivered
atients receiving tuberculosis skin test results, a referral for
rther evaluation if a test is positive, starting therapy after it was
commended), but they also identiﬁed important gaps in care in
ed of improvement. These gaps include the initial linkage to
reening for LTBI, completing a medical evaluation after being
ferred, being recommended for treatment after a medical
aluation, and completing treatment once started.
The authors also found that higher proportions of people tested
sitive for LTBI in low- and middle-income countries (LMICs)
rsus high-income countries, 61.3% and 24.8%, respectively.7
eatment completion rates also differed between LMICs and high-
come countries. Of people who started preventive therapy, only
% of those in LMICs completed treatment, as compared to 70% in
gh-income countries. When comparing treatment completion
ong those who were eligible, less than 17% in LMICs, and 23% in
gh-income countries completed treatment; not nearly as large a
fference as among those starting treatment.7 A variety of factors
ntributing to these gaps were highlighted, including low TB risk
rceptions and ﬁnancial hardships among patients, to the lack of
ovider knowledge regarding LTBI treatment.7
This review highlights that studies on LTBI management that
cus on LTBI diagnosis (usually as a result of contact investiga-
ns) and adherence to treatment, need to recognize the various
terim steps where patient attrition can occur in order to improve
e quality of LTBI care in its entirety. The authors found fewer
sses to occur among high-risk populations (i.e., close contacts or
tients with serious medical disorders), likely as a result of
tensiﬁed follow-up, supporting the need for improved quality of
re to ensure successful completion of preventive TB therapy.7
 Quality of care for active TB
Only one systematic review that explicitly reviewed studies on
ality of TB care was identiﬁed; the review was performed in
dia. Satyanarayana and colleagues conducted a systematic
view of Indian studies on health care providers’ knowledge
d self-reported practices regarding TB, and used the Interna-
nal Standards for TB Care (ISTC) to benchmark quality of care.8
 the 47 studies identiﬁed in the review, 12 used medical records
d 35 were based on questionnaires. None assessed actualPlease cite this article in press as: Cazabon D, et al. Quality of tubercu
in the care cascade. Int J Infect Dis (2016), http://dx.doi.org/10.101practice using standardized (simulated) patients. Ten of 22 studies
evaluating provider knowledge about TB diagnosis found that less
than half of providers had correct knowledge of using sputum
microscopy for persons with typical TB symptoms. Of the four
studies that assessed self-reported practices by providers, three
found that less than one-fourth reported ordering sputum smears
for persons with typical TB symptoms. In 11 of 14 studies that
assessed treatment, less than one-third of providers knew the
standard four-drug regimen (HRZE: isoniazid, rifampicin, pyr-
azinamide, ethambutol) for drug-sensitive TB. Across all stan-
dards, providers had better knowledge as compared to self-
reported practices. In this review, 11 studies included both public
and private providers; in general, public sector providers had
relatively higher levels of appropriate knowledge as well as
practice.
Other systematic reviews have focused on TB diagnostic delays,
which is a surrogate for quality of TB care. In a systematic review of
39 studies, including data from 45 countries, Sreeramareddy and
colleagues estimated that the median time interval between the
onset of symptoms suggestive of PTB and the patient’s ﬁrst contact
with a health care provider was 31.7 days (patient delay).9 The
median time interval between the ﬁrst health consultation and the
date of diagnosis was 28.4 days (health system delay). The median
time interval between the onset of PTB symptoms and the
initiation of anti-TB therapy was 67.8 days (total delay).
A subsequent systematic review that focused on 23 studies
from different parts of India, identiﬁed that the median patient,
diagnostic, and total delays were 18.4 days (interquartile range
(IQR) 14.3–27 days), 30 days (IQR 24.5–35.4 days), and 55.3 days
(IQR 46.5–61.5 days), respectively.10 This review also found that
Indian TB patients, on average, are diagnosed after three health
care provider visits. These studies show that TB diagnosis may be
delayed even when patients present with overt TB symptoms, and
underscores the need to address this major diagnostic gap.losis care in high burden countries: the urgent need to address gaps
6/j.ijid.2016.10.016
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Figure 2. Analysis of the HIV cascade of care, comparing the UNAIDS targets for
2020 with global estimates for 2014/15.
Source: Levi et al. BMJ Global Health 201611 (Open Access, under Creative Commons
License).
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analysis to identify and address major gaps in the continuum and
quality of HIV care, from diagnosis to successful virological
suppression after antiretroviral therapy.11 This helps assess
progress towards the Joint United Nations Programme on HIV/
AIDS (UNAIDS) ‘90–90–90 targets’, which aim to diagnose 90% of
all HIV-positive people, provide antiretroviral therapy (ART) for
90% of those diagnosed, and achieve viral suppression for 90% of
those treated. Figure 2 illustrates a global HIV care cascade and
highlights the current gaps at each step of the cascade.11
While published analyses of TB care cascades are scarce, a
recent analysis from India provides useful insights into how this
approach can help identify gaps in quality of TB care.12 Subbara-
man and colleagues conducted a cascade of care analysis for TB in
India using data from the Revised National TB Control Programme
(RNTCP), the WHO, and targeted systematic reviews.12 The study
estimated that over 25% of prevalent TB cases in 2013 were not
being evaluated at governmental TB diagnostic centers (Figure 3).
Of the 1.9 million cases that made contact with the public health
facilities, about half a million cases were either not correctly
diagnosed or were not put on treatment once diagnosed. The study
used recurrence-free survival as the endpoint of the cascade rather
than treatment completion (used by national TB programs). The
authors suggested that routine follow-up with patients after
treatment ends may be equally as important as monitoring
adherence to treatment, due to considerable rates of post-
treatment TB recurrence. This will facilitate early detection of
relapse cases. Of note, the setting-speciﬁc context is important for
understanding the cascade of care, as in some settings re-infection
is common and thus recurrence-free survival may be less likely to
reﬂect the quality of TB care received.
Traditionally, studies of quality of TB care have mostly relied on
knowledge-assessment questionnaires (e.g., ‘vignettes’), direct
observation of providers, recall-based patient surveys, and chart
abstraction (e.g., prescription audit). However, these methods may
not reﬂect actual practice.13,14 Consequently, standardized or
simulated patients (SPs) are increasingly used in low-income
countries to assess quality of care for a variety of conditions.15–18
Relative to other methods of measuring quality of care, data from
SPs yield an assessment of provider practice that is free fromFigure 3. The cascade of care for all forms of tuberculosis in the 2013 Revised National T
intervals.
Source: Subbaraman R et al. PLoS Med 201612 (Open Access, under Creative Commons
Please cite this article in press as: Cazabon D, et al. Quality of tuberculo
in the care cascade. Int J Infect Dis (2016), http://dx.doi.org/10.1016observation bias, less vulnerable to recall bias, and more complete
than medical records. Furthermore, SPs permit estimates of case
detection rates, since illnesses are ﬁxed by design. Finally, because
cases are standardized, the methodology allows for qualityuberculosis Control Programme (RNTCP) in India. Error bars depict 95% conﬁdence
 License).
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Figure 4. The tuberculosis cascade of care for multidrug-resistant tuberculosis
(MDR-TB) patients detected and treated by the 2013 Revised National Tuberculosis
Control Programme (RNTCP) in India. Error bars depict 95% conﬁdence intervals for
each estimate.
Source: Subbaraman R et al. PLoS Med 201612 (Open Access, under Creative
Commons License).
D. Cazabon et al. / International Journal of Infectious Diseases xxx (2016) xxx–xxx4
G Model
IJID 2747 1–6mparisons across different care providers (e.g., public vs.
ivate).
Das and colleagues recently published the ﬁrst validation study
 the use of SPs for assessing quality of TB care.16 Four
ototypical cases, two for presumed TB and one each for
nﬁrmed TB and suspected multidrug-resistant TB (MDR-TB),
ere presented by 17 SPs, with 250 SP interactions with
0 consenting health care providers in Delhi. The researchers
so used vignettes to assess provider knowledge of presumed TB.
rrect case management was benchmarked using Standards for
 Care in India (STCI).19 The proportion of SPs correctly detected
 have TB was strikingly low at 5%, with a high correlation noted
tween SP recall and audio recordings. Across all cases, only
 out of 250 (21%; 95% conﬁdence interval (CI) 16–26%) were
rrectly managed. Correct management was higher among
aliﬁed doctors (adjusted odds ratio 2.41, 95% CI 1.17–4.93) as
mpared to all informal providers and practitioners of alternative
rms of medicine. Provider knowledge based on responses to the
gnettes was markedly more consistent with the recommenda-
ns outlined in the STCI than their practice. For example, while
% said they would order a sputum test or X-ray for suspected TB,
ly 10% actually did so when the SP visited them.
Based on the success of this pilot project in identifying gaps in
ality of TB care, a similar methodology was used in three Indian
ties to assess how pharmacists managed persons with TB
mptoms. Indian pharmacists are frequently consulted by patients
r over-the-counter medications.20 Satyanarayana and colleagues
ained SPs to present as two cases.20 Case 1 was an SP presenting
ith 2–3 weeks of cough and other typical TB symptoms. Case 2 was
 SP presenting with a laboratory test report conﬁrming PTB. SPs
mpleted 1200 interactions in 622 pharmacies in the cities of Delhi,
umbai, and Patna. The researchers deﬁned ideal management for
th cases a priori as referral to any health care provider without
tibiotics or steroids being dispensed. Ideal management was seen
 only 13% of pharmacies that received case 1 SPs. However, for case
SPs, the ideal management proportion increased to 62%. The use of
oad-spectrum antimicrobials was nearly half in case 2 interactions
 compared to case 1 interactions. Referrals were signiﬁcantly more
mmon when SPs carried with them evidence of TB (i.e., positive
utum test report), thus making the diagnosis apparent to
armacists.
Thus, the use of the SP methodology allowed the researchers to
ow that Indian pharmacists can delay the diagnosis of TB by
spensing broad-spectrum antibiotics (including ﬂuoroquino-
nes) and not referring persons with typical TB symptoms for
sting. However, the study also showed that, contrary to popular
lief, none of the pharmacists in the three cities was dispending
st-line anti-TB medications over the counter. These ﬁndings are
ghly relevant to India, could help prevent antibiotic abuse, and
crease referrals from pharmacists.
These novel SP studies present direct evidence that improving
e quality of care in HBCs with complex health systems such as
dia must be a priority. The SP methodology can feasibly be
plicated in other HBCs, as they can inform quality improvement
I) programs to address gaps at different stages of the continuum
 TB care.
 Quality of care for drug-resistant TB
Mounting evidence demonstrates the primary transmission of
ug-resistant TB (DR-TB) strains, but the emergence and
rsistence of TB drug resistance also highlights the shortcomings
 the current quality of TB care. Data demonstrate frequent delays
 the diagnosis of MDR/RR-TB, and globally less than one quarter
 the estimated MDR/RR-TB patients are detected and reported to
tional surveillance systems.2 The empirical management of TBPlease cite this article in press as: Cazabon D, et al. Quality of tubercu
in the care cascade. Int J Infect Dis (2016), http://dx.doi.org/10.101without drug susceptibility testing (DST), inappropriate drug
regimens, and insufﬁcient attention to concurrent social support
for patients to facilitate treatment completion are major drivers of
DR-TB. The WHO has proposed ﬁve priority actions to tackle the
global DR-TB crisis: (1) prevent the development of drug resistance
through the high quality treatment of drug-sensitive TB; (2)
expand the rapid testing and detection of DR-TB cases; (3) provide
immediate access to effective treatment and proper care; (4)
prevent transmission through infection control; and (5) increase
political commitment with ﬁnancing. Unfortunately, HBCs are yet
to address these priority actions to tackle DR-TB. In many
countries, less than half of all patients with MDR-TB are on
second-line drug therapy.2
While there have been no systematic reviews on the quality of
care for DR-TB, reviews discussed earlier show critical gaps in
service delivery among studies involving patients with DR-TB.
Satyanarayana and colleagues found one study that examined
quality of care for DR-TB, which identiﬁed that only 39% of health
care providers reported conducting DST for eligible TB cases.8
Moreover, using SPs, Das and colleagues found that even among
qualiﬁed, trained doctors in India, a DST was rarely ordered for a SP
with classic TB symptoms and a clear history of previous,
incomplete therapy.16
In the Indian cascade of TB care analysis by Subbaraman and
colleagues, data for MDR-TB patients were analyzed separately.12
As shown in Figure 4, the cascade suggests that the vast majority of
MDR-TB patients who present to public sector diagnostic facilities
are not diagnosed with drug resistance, highlighting an urgent
need to move towards universal DST, as recommended by the End
TB Strategy.12 Of note, outcomes for MDR-TB patients were
considerably worse than for drug-sensitive TB patients, with only
10.6% of MDR-TB patients achieving recurrence-free survival.
Suboptimal care for DR-TB is not limited to India. The WHO
reported that in 2015, there were an estimated 480 000 cases of
MDR-TB globally and 100 000 cases of RR-TB. Of these, only
130 000 (approximately 23%) were detected and reported.2
Unless this gap is addressed, MDR-TB will continue to be a major
challenge. Even after diagnosis, only about half of these patients
with DR-TB were successfully treated. This means access
to second-line therapy is suboptimal, and patients are not
getting the support they need to complete the long treatment
for DR-TB.2losis care in high burden countries: the urgent need to address gaps
6/j.ijid.2016.10.016
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Table 1
Advantages of the cascade of care model for monitoring tuberculosis (TB) programs
 Helps policymakers and program staff to visualize the largest gaps in care
delivery to facilitate the design of targeted interventions to reduce those
gaps
 Shifts program goals away from ‘coverage’ of a population with TB health
services and towards engagement and retention of all TB patients at
each step of care
 Places ‘notiﬁed’ TB patients in the larger context of the overall TB
population or the TB population reaching care, which helps reveal new
gaps in care
 Shifts program metrics away from case notiﬁcation and treatment
completion to more rigorous outcomes such as 1-year TB recurrence-free
survival
 Cascades for TB sub-populations (e.g., smear-negative or multidrug-
resistant patients) may identify unique points of attrition requiring
different interventions from the overall TB population
 Sub-population cascades have also been used in HIV to identify high-risk
and vulnerable demographic groups, such as adolescents and incarcerated
individuals
 Incorporation of the cascade into routine monitoring of TB programs may
allow the development of uniﬁed metrics and global targets, as UNAIDS
has
done for the ‘90–90–900 HIV/AIDS strategy
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Patient-centric, quality TB care is critical for reaching the End TB
Strategy targets, and yet, it is clear that many patients do not
receive such care in HBCs. While the ISTC have laid out the
expectations for quality standards,21 the present review shows
that the quality of care in both the public and private sectors does
not meet these standards, and serious implementation gaps
continue to be a concern in many settings.
In 2015, Me´decins Sans Frontie`res (MSF) and the Stop TB
Partnership published a report called Out of step. This was based on a
survey of 24 high TB burden countries, to assess policy adoption in
these settings.22 Serious implementation gaps were identiﬁed in the
survey. The study showed heavy reliance by countries on inaccurate
smear microscopy, while only eight countries had revised their
national diagnostic algorithms to include the Xpert MTB/RIF
(Cepheid Inc., USA) as the frontline test for individuals with
suspected TB (instead of sputum microscopy). While intermittent
therapy for drug-sensitive TB is suboptimal compared to daily
therapy, six countries still offered them. So, it is important for the TB
community to acknowledge these implementation gaps and ﬁnd
ways to raise the resources that are necessary for providing quality
care that is consistent with international standards.23 Achieving
political will and consensus on this issue will be critical.
6. Quality improvement (QI) interventions
TB programs must start to systematically analyze gaps in their
care cascades and work towards measuring and incorporating
quality of care indicators, in addition to routine coverage
indicators. This can be achieved using the established framework
of QI, which is a proven, effective way to improve care for patients
and to improve practice for health care providers. Health care
systems are inherently complex, but using a systematic approach
enables the optimization of processes and interventions. QI should
be a continuous process and an integral part of adding value to
patient care and to the health care delivery system.3,4
In TB, there is a paucity of projects that speciﬁcally aim to
establish and test QI interventions. However, there are many
examples of interventions that have improved quality of TB care in
both public and private sectors. As an example, Davis and
colleagues prospectively evaluated TB diagnostic services at ﬁve
primary health care facilities in Uganda over 1 year, after
introducing a real-time, electronic performance-monitoring sys-
tem.24 They collected data on every clinical encounter, and
measured quality using indicators derived from the ISTC. In
2009, there were 62 909 adult primary care visits at the facilities
included in the study. During the ﬁrst quarter of 2009, clinicians
referred only 21% of patients with cough greater than or equal to
2 weeks for sputum smear microscopy and only 71% of patients
with a positive sputum examination for TB treatment. These
proportions increased to 53% and 84%, respectively, in the fourth
quarter of 2009. The cumulative probability that a smear-positive
patient with cough greater than or equal to 2 weeks would be
appropriately evaluated and referred for treatment rose from 11%
to 34% (p = 0.005). The quarterly number of TB cases identiﬁed and
prescribed treatment also increased four-fold, from 5 to 21.
A subsequent follow-up study in Uganda evaluated the beneﬁts
of a multi-component health system strengthening intervention
for improving quality of care.25 Same-day smear microscopy was
implemented at six health centers, and a performance feedback
initiative was implemented in which health care providers were
given a monthly ‘report card’ on their adherence to speciﬁc ISTC
indicators. These included the proportion of adults with cough
referred for sputum examination, the proportion completing
sputum examination, and the proportion of smear-positivePlease cite this article in press as: Cazabon D, et al. Quality of tuberculo
in the care cascade. Int J Infect Dis (2016), http://dx.doi.org/10.1016patients initiating treatment. Same-day sputum microscopy
increased the proportion of patients receiving ISTC-adherent care
by 14% (95% CI 10–18), and performance feedback increased the
proportion of patients receiving ISTC-adherent care by 15% (95% CI
10–20). Thus, these studies show that real-time performance
monitoring and targeted health system strengthening interven-
tions can improve adherence to internationally accepted standards
of TB care.
In the private sector, where quality of TB care can deviate
considerably from expected standards, several public–private
partnerships have attempted to improve quality of care, with
varying degrees of success, as reviewed elsewhere.26 India’s RNTCP
and state and municipal governments have recently reported
success with innovative models of private sector engagement.27 In
urban pilots in Mumbai, Patna, and Mehsana, the Indian TB
program has engaged a large number of private providers and has
greatly increased the numbers of private TB case notiﬁcations. In
addition, the Indian TB program has improved the diagnosis of TB
by offering free vouchers for tests such as GeneXpert, provided
patients free daily ﬁxed dose combinations, and improved
adherence support to patients managed in the private sector,
with good treatment completion rates.27
7. Conclusions
In order to improve TB care, with a view to achieving the
ambitious targets set out in the End TB Strategy, we need to
increase access to TB care and simultaneously ensure that the
care provided is of sufﬁciently high quality.3,4 Health care
systems and national TB programs will therefore need to think
beyond access and coverage of health care services, and start
systematically measuring and improving quality of TB care.
Routine evaluation of delays in TB diagnosis and SP studies can
help to identify and monitor deﬁciencies in health systems and
provider behavior that may compromise the diagnostic evalua-
tion of TB patients. As shown in Table 1, regular analysis of the
cascade of care can help shift metrics away from the focus on
coverage of health services and towards a focus on engagement
and retention of patients to ensure that all TB patients achieve
an optimal outcome of treatment completion and recurrence-
free survival. The institution of structured QI programs as an
integral part of all national TB programs, supported by clear
metrics that take into account setting-speciﬁc contexts, will besis care in high burden countries: the urgent need to address gaps
/j.ijid.2016.10.016
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